Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally, Peter Whitaker, Paul Peckham, Daniel
Greally, Peter
Whitaker, Paul
Peckham, Daniel
Advisors
Editors
Other Contributors
Date
2012-06
Date Submitted
Keywords
Other Subjects
Subject Mesh
Administration, Inhalation
Anti-Bacterial Agents
Chronic Disease
Cystic Fibrosis
Drug Resistance, Bacterial
Humans
Models, Biological
Pseudomonas Infections
Pseudomonas aeruginosa
Respiratory Tract Infections
Anti-Bacterial Agents
Chronic Disease
Cystic Fibrosis
Drug Resistance, Bacterial
Humans
Models, Biological
Pseudomonas Infections
Pseudomonas aeruginosa
Respiratory Tract Infections
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
Abstract
Pseudomonas aeruginosa (Pa) is the predominant pathogen infecting the airways of patients with cystic fibrosis (CF). Initial colonization is usually transient and associated with non-mucoid strains, which can be eradicated if identified early. This strategy can prevent, or at least delay, chronic Pa infection, which eventually develops in the majority of patients by their late teens or early adulthood. This article discusses the management and latest treatment developments of Pa lung infection in patients with CF, with a focus on nebulized antibiotic therapy.
Language
en
ISSN
1473-4877
eISSN
ISBN
DOI
10.1185/03007995.2012.674500
PMID
22401602